
What is claimed is:

1 . A compound of formula 1 :




(1)

and/or at least one pharmaceutically acceptable salt thereof wherein

A^1 is CH;

A^4 and A^5 are independently CR^2 ~~or N~~H;

A^2 and A^3, together with B ring, ~~are a 5 membered heteroaryl or heterocycle, said 5-membered heteroaryl or heterocycle is selected from~~is



~~(2)~~ ~~(3)~~ ~~(4)~~ ~~(5)~~ ~~(6)~~. (3)

Wherein,


~~t is 1,2 or 3 and~~

R^3 is independently chosen from H, C_1-C_6 alkyl,C_2-C_8 alkenyl, C_2-C_8 alkynyl, C_6-C_{14} aryl, C_3-C_9 membered cycloalkyl, -C(O)OR^b, -CN, -C(O)NR^cR^d, -NR^cR^d, -$NR^cC(O)R^a$, -$NR^cS(O)_nR^e$, -$NR^cS(O)_nNR^fR^g$, -$NR^cC(O)OR^b$, -$NR^cC(O)NR^dR^e$, -NO_2, -OR^b, -OC(O)R^a, -OC(O)NR^cR^d, -$S(O)_nR^e$, -$S(O)_nNR^cR^d$, halo, halo C_1-C_6 alkyl, heteroaryl, and heterocycle; and each of said above alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl

and heterocycle can be optionally substituted by one or more groups independently chosen from ~~optionally substituted~~ C_1-C_6 alkyl, ~~optionally substituted~~ C_2-C_8 alkenyl, ~~optionally substituted~~ C_2-C_8 alkynyl, ~~optionally substituted aryl, optionally substituted~~ C_3-C_9 cycloalkyl, -OH, oxo, $-C(O)R^a$, $-C(O)OR^b$, -CN, $-C(O)NR^cR^d$, $-NR^cR^d$, $-NR^cC(O)R^a$, $-NR^cS(O)_nR^e$, $-NR^cS(O)_nNR^fR^g$, $-NR^cC(O)OR^b$, $-NR^cC(O)NR^dR^e$, $-NO_2$, OR^b, $-S(O)_nR^e$, $-S(O)_nNR^cR^d$, halo, ~~optionally substituted~~ halo C_1-C_6 alkyl, ~~optionally substituted~~ heteroaryl, and ~~optionally substituted~~ heterocycle, optionally substituted with –C(O) C_1-C_4 alkyl, further wherein each of alkyl is optionally substituted with -CN or -OH;

~~provided that, when A^4 is not CR^2, A^2 and A^3, together with B ring, are seleted from structure (3), (5) or (6);~~

~~------ is a single bond or a double bond;~~



or A^2 and A^3, together with B ring, is (6) ,

wherein,

R^3 is independently chosen from H, C_1-C_6 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, C_6-C_{14} aryl, C_3-C_9 membered cydoalkyl;

R^1 is heteroaryl, optionally substituted by one or more groups independently chosen from C_1-C_6 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, C_6-C_{14} aryl, C_3-C_9 cycloalkyl, oxo, $-C(O)R^a$, $-C(O)OR^b$, -CN, $-C(O)NR^cR^d$, $-NR^cR^d$, $-NR^cC(O)R^a$, $-NR^cS(O)_nR^e$, $-NR^cS(O)_nNR^fR^g$, $-NR^cC(O)OR^b$, $-NR^cC(O)NR^dR^e$, $-NO_2$, $-OR^b$, $-S(O)_nR^e$, $-S(O)_nNR^cR^d$, halo, halo C_1-C_6 alkyl, heteroaryl, and heterocycle;

~~R^2 are independently chosen from H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, $-C(O)R^a$, $-C(O)OR^b$, -CN, $-C(O)NR^cR^d$, $-NR^cR^d$, $-NR^cC(O)R^a$, $-NR^cS(O)_nR^e$, $-NR^cS(O)_nNR^fR^g$, $-NR^cC(O)OR^b$, $-NR^cC(O)NR^dR^e$, $-NO_2$, $-OR^b$, $-OC(O)R^a$, $-OC(O)NR^cR^d$, $-S(O)_nR^e$,~~

~~$S(O)_nNR^eR^d$, halo, haloalkyl, heteroaryl, and heterocycle; and each of said above alkyl, alkenyl, alkynyl, aryl, cycloalkyl, haloalkyl, heteroaryl and heterocycle can be optionally substituted by one or more groups independently chosen from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, OH, oxo, $C(O)R^a$, $C(O)OR^b$, CN, $C(O)NR^eR^d$, NR^eR^d, $NR^eC(O)R^a$, $NR^eS(O)_nR^e$, $NR^eS(O)_nNR^fR^g$, $NR^eC(O)OR^b$, $NR^eC(O)NR^dR^e$, NO_2, OR^b, $S(O)_nR^e$, $S(O)_nNR^eR^d$, halo, optionally substituted haloalkyl, optionally substituted heteroaryl, and optionally substituted heterocycle;~~

R^a, R^b, R^c, R^d, R^e, R^f and R^g are each independently chosen from H, ~~optionally substituted~~ C_1-C_6 alkyl, ~~optionally substituted~~ C_2-C_8 alkenyl, ~~optionally substituted~~ C_2-C_8 alkynyl C_6-C_{14} ~~optionally substituted~~ aryl, optionally substituted with C_1-C_6 alkyl or halo, C_3-C_9 cycloalkyl, ~~optionally substituted~~ halo C_1-C_6 alkyl, ~~optionally substituted~~ heteroaryl, and ~~optionally substituted~~ heterocycle,

or R^a and R^c, and/or R^c and R^d, and/or R^c and R^e, and/or R^c and R^f, and/or R^d and R^e, and /or R^g and R^f together with the atom(s) to which they are attached, form a 3-10 membered ~~optionally substituted~~ heterocycle ring; and

for each occurrence, n is independently 0, 1 , or 2.


2. The compound according to Claim 1, wherein said R^3 is chosen from H, OH, CN, NO_2, halo, C_1-C_6 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, C_6-C_{14} aryl, C_3-C_9 cycloalkyl, heteroaryl, and heterocycle, wherein each of the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycle is optionally substituted by one or more groups independently chosen from ~~optionally substituted~~ C_1-C_6 alkyl, ~~optionally substituted~~ C_2-C_8 alkenyl, ~~optionally substituted~~ C_2-C_8 alkynyl, ~~optionally substituted~~ C_6-C_{14} aryl, ~~optionally substituted~~ C_3-C_9 cycloalkyl, -OH, oxo, $-C(O)R^a$, $-C(O)OR^b$, -CN, $-C(O)NR^cR^d$, $-NR^cR^d$, $-NR^cC(O)R^a$, $-NR^cS(O)_nR^e$, $-NR^cS(O)_nNR^fR^g$, $-NR^cC(O)OR^b$, $-NR^cC(O)NR^dR^e$, $-NO_2$, OR^b, $-S(O)_nR^e$, $-S(O)_nNR^cR^d$, halo, ~~optionally substituted~~ halo C_1-C_6 alkyl, ~~optionally substituted~~ heteroaryl, and ~~optionally substituted~~ heterocycle optionally substituted with $-C(O)$ C_1-C_4 alkyl, further wherein each of alkyl is optionally substituted with –CN or -OH.

3. The compound according to ~~any one of~~ Claims ~~1~~-2, wherein said R^3 is chosen from H, C_1-C_6 alkyl, C_6-C_{14} aryl, C_3-C_9 cycloalkyl, heteroaryl, and heterocycle, wherein each of the alkyl, aryl, cycloalkyl, heteroaryl, and heterocycle is optionally substituted by one or more groups independently chosen from C_1-C_6 alkyl -OH, -C(O)R^a, -CN, -NR^cR^d, - OR^b, -$S(O)_nR^e$, - $S(O)_nNR^cR^d$, halo, and heterocycle optionally substituted with –C(O) C_1-C_4 alkyl, further wherein each of alkyl is optionally substituted with –CN or -OHA^5 ~~is N or CH~~.

4. The compound according to ~~any one of~~ Claims 1~~–3, wherein A^5 is CH.~~


~~5. The compound according to any one of Claims 1-4, wherein A^4 is CH~~

~~6. The compound according to any one of Claims 1–5, wherein A^2 and A^5, together with~~



~~the Bring is (3)~~.


~~7. The compound according to any one of Claims 1–5, wherein A^2 and A^5, together with~~



~~the Bring is selected from (5) or (6)~~.


~~8. The compound according to any one of Claims 1–4, wherein A^4, is N.~~

~~9. The compound of Claim 8, wherein A^2 and A^3, together with B ring is~~




~~(4)~~.

~~10. The compound of Claim 8, wherein A^2 and A^3, together with B ring is selected from~~



~~(2) (3) (5) or (6)~~


~~11. The compound according to any one of Claims 1–10~~, wherein R^1 is a heteroaryl chosen from the following structures



wherein each of which is optionally substituted by one or more groups independently chosen from C_1-C_6 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, aryl, C_3-C_9 cycloalkyl, halo C_1-C_6 alkyl, heteroaryl, heterocycle, oxo, $-C(O)R^a$, $-C(O)OR^b$, -CN, $-C(O)NR^cR^d$, $-NR^cR^d$, $-NR^cC(O)R^a$, $-NR^cS(O)_nR^e$, $-NR^cS(O)_nNR^fR^g$, $-NR^cC(O)OR^b$, $-NR^cC(O)NR^dR^e$, $-NO_2$, $-OR^b$, $-OC(O)R^a$, $-OC(O)NR^cR^d$, $-S(O)_nR^e$, $-S(O)_nNR^cR^d$ and halo~~, and wherein each of the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, haloalkyl, heteroaryl and heterocycle is optionally substituted by one or more groups independently chosen from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, OH, oxo, $C(O)R^a$, $C(O)OR^b$, CN, $C(O)NR^eR^d$, NR^eR^d, $NR^eC(O)R^a$, $NR^eS(O)_nR^e$, $NR^eS(O)_nNR^fR^g$, $NR^eC(O)OR^b$, $NR^eC(O)NR^dR^e$, NO_2, OR^b, $S(O)_nR^e$, $S(O)_nNR^eR^d$, halo, optionally substituted haloalkyl, optionally substituted heteroaryl, and optionally substituted heterocycle~~;

wherein R^a, R^b, R^c, R^d, R^e, R^f and R^g are each independently chosen from H, C_1-C_6 alkyl, C_6-C_{14} aryl, C_3-C_9 cycloalkyl, halo C_1-C_6 alkyl, heteroaryl, and heterocycle, further wherein each of the alkyl, aryl, cycloalkyl, heteroaryl, and heterocycle in R^a, R^b, R^c, R^d, R^e, R^f and R^g is optionally substituted by one or more substitutents independently selected from halo and C_1-C_6 alkyl.

~~12~~ 5. The compound according to Claim ~~11~~4, wherein R^1 is a heteroaryl chosen from




wherein each of which is optionally substituted by one or more groups independently chosen from C_1-C_6 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, C_6-C_{14} aryl, C_3-C_9 cycloalkyl, halo C_1-C_6 alkyl, heteroaryl, heterocycle, oxo, $-C(O)R^a$, $-C(O)OR^b$, -CN, $-C(O)NR^cR^d$, -

NR^cR^d, - $NR^cC(O)R^a$, -$NR^cS(O)_nR^e$, -$NR^cS(O)_nNR^fR^g$, -$NR^cC(O)OR^b$, -$NR^cC(O)NR^dR^e$, -NO_2, - OR^b, -$OC(O)R^a$, -$OC(O)NR^cR^d$, -$S(O)_nR^e$, -$S(O)_nNR^cR^d$ and halo~~, and wherein each of the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, haloalkyl, heteroaryl and heterocycle is optionally substituted by one or more groups independently chosen from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, -OH, oxo, -$C(O)R^a$, -$C(O)OR^b$, -CN, -$C(O)NR^eR^d$, -NR^eR^d, -$NR^eC(O)R^a$, -$NR^eS(O)_nR^e$, -$NR^eS(O)_nNR^fR^g$, -$NR^eC(O)OR^b$, -$NR^eC(O)NR^dR^e$, -NO_2, OR^b, -$S(O)_nR^e$, -$S(O)_nNR^eR^d$, halo, optionally substituted haloalkyl, optionally substituted heteroaryl, and optionally substituted heterocycle~~;

wherein R^a, R^b, R^c, R^d, R^e, R^f and R^g are each independently chosen from H, C_1-C_6 alkyl, C_6-C_{14} aryl, C_3-C_9 cycloalkyl, halo C_1-C_6 alkyl, heteroaryl, and heterocycle, further wherein each of the alkyl, aryl, cycloalkyl, heteroaryl, and heterocycle in R^a, R^b, R^c, R^d, R^e, R^f and R^g is optionally substituted by one or more substitutents independently selected from halo and C_1-C_6 alkyl.

6. The compound according to Claim 4, wherein R^1 is a heteroaryl chosen from



wherein each of which is optionally substituted by one or more groups independently chosen from C_1-C_6 alkyl, haloalkyl, -NR^cR^d, -$NR^cS(O)_nR^e$, and halo;

wherein, R^b, R^c, R^d, and R^e are each independently chosen from H, C_1-C_6 alkyl, C_6-C_{14} aryl, C_3-C_9 cycloalkyl, halo C_1-C_6 alkyl, further wherein aryl, in R^b, R^c, R^d, and R^e is optionally substituted by one or more substitutents independently selected from halo and C_1-C_6 alkyl.

~~137~~. The compound according to ~~any one of~~ Claims ~~1–12~~ 6, wherein R^1 is , which is optionally substituted with one or more groups independently chosen from:

~~- alkyl, alkenyl, alkynyl, wherein each of which is optionally substituted by one or more groups independently chosen from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, OH, oxo, $C(O)R^a$, $C(O)OR^b$, CN, $C(O)NR^eR^d$, NR^eR^d, $NR^eC(O)R^a$, $NR^eS(O)_nR^e$, $NR^eS(O)_nNR^fR^g$, $NR^eC(O)OR^b$, $NR^eC(O)NR^dR^e$, NO_2, OR^b, $S(O)_nR^e$, $S(O)_nNR^eR^d$, halo, optionally substituted~~ halo C_1-C_6 alkyi, ~~optionally substituted heteroaryl, and optionally substituted heterocycle~~;

~~$C(O)NR^eR^d$;~~

$-NR^cR^d$;

$-OR^b$;








-halo;








~~-cyano;~~








$-NR^cS(O)_nR^e$,








wherein ~~R^a~~, R^b, R^c, R^d, ~~R^e~~, ~~R^f~~ and ~~R^g~~ R^c are each independently chosen from H, C_1-C_6 alkyl, aryl, C_3-C_9 cycloalkyl, halo C_1-C_6 alkyl, ~~heteroaryl, and heterocycle~~, wherein ~~each of the alkyl,~~ aryl~~, cycloalkyl, heteroaryl, and heterocycle~~ in ~~R^a~~, R^b, R^c, R^d, ~~R^e~~, ~~R^f~~ and ~~R^g~~ R^c is optionally substituted by one or more substitutents independently selected from halo and C_1-C_6 alkyl.








~~148~~. A compound selected from following compounds ~~1 to 184~~ and/or at least one pharmaceutically acceptable salt:








Compound	Structure
49	
50	
51	
52	
53	
54	
55	







56	
57	
58	
59	
60	
61	
62	








63	
64	
65	
66	
67	
68	
69	







70	
71	
72	
73	
74	
75	
76	





77	
78	
79	
80	
81	
82	
83	

84	
85	
86	
87	
147	
148	
149	

150	
152	
155	
156	
157	
158	

161	
162	
163	
164	
165	
167	
168	

169	
170	
171	
172	
174	
175	

179	
180	
181	
182	

159. A pharmaceutical composition comprising at least one compound and/or at least one pharmaceutically acceptable salt thereof according to any one of Claims 1 -14-8 and at least one pharmaceutically acceptable carrier.

1610. A method of inhibiting the activity of PI3K and/or mTOR comprising contacting the enzyme with an effective amount of at least one compound and/or at least one pharmaceutically acceptable salt thereof according to any one of Claims 1 -148.


~~17. A method of treating cancer responsive to inhibition of PI3K and/or mTOR comprising administering to a subject in need thereof an effective amount of at least one compound and/or at least one pharmaceutically acceptable salt thereof according to any one of Claims 1 -14.~~

~~18~~11. A use of at least one compound and/or at least one pharmaceutically acceptable salt thereof according to any one of Claims 1 -~~14~~ 8 in the manufacture of a medicament for inhibiting the activity of PI3K and/or mTOR.

~~19~~12. A use of at least one compound and/or at least one pharmaceutically acceptable salt thereof according to any one of Claims 1 -~~14~~ 8 in the manufacture of a medicament for treating cancer.

What is claimed is:

1 . A compound of formula 1 :




(1)

and/or at least one pharmaceutically acceptable salt thereof wherein

A^1 is CH;

A^4 and A^5 are independently CH;


A^2 and A^3, together with B ring, is



(3)Wherein,

R^3 is independently chosen from H, C_1-C_6 alkyl,C_2-C_8 alkenyl, C_2-C_8 alkynyl, C_6-C_{14} aryl, C_3-C_9 membered cycloalkyl, -C(O)OR^b, -CN, -C(O)NR^cR^d, -NR^cR^d, -$NR^cC(O)R^a$, -$NR^cS(O)_nR^e$, -$NR^cS(O)_nNR^fR^g$, -$NR^cC(O)OR^b$, -$NR^cC(O)NR^dR^e$, -NO_2, -OR^b, -$OC(O)R^a$, -$OC(O)NR^cR^d$, -$S(O)_nR^e$, -$S(O)_nNR^cR^d$, halo, halo C_1-C_6 alkyl, heteroaryl, and heterocycle; and each of said above alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl and heterocycle can be optionally substituted by one or more groups independently chosen from C_1-C_6 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, C_3-C_9 cycloalkyl, -OH, oxo, -$C(O)R^a$, -C(O)OR^b, -CN, -C(O)NR^cR^d, -NR^cR^d, -$NR^cC(O)R^a$, -$NR^cS(O)_nR^e$, -$NR^cS(O)_nNR^fR^g$, -$NR^cC(O)OR^b$, -$NR^cC(O)NR^dR^e$, -NO_2, OR^b, -$S(O)_nR^e$, -$S(O)_nNR^cR^d$,

halo halo C_1-C_6 alkyl, heteroaryl, and heterocycle, optionally substituted with –C(O) C_1-C_4 alkyl, further wherein each of alkyl is optionally substituted with -CN or -OH;



or A^2 and A^3, together with B ring, is (6) ,

wherein,

R^3 is independently chosen from H, C_1-C_6 alkyl,C_2-C_8 alkenyl, C_2-C_8 alkynyl, C_6-C_{14} aryl, C_3-C_9 membered cydoalkyl;

R^1 is heteroaryl, optionally substituted by one or more groups independently chosen from C_1-C_6 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, C_6-C_{14} aryl, C_3-C_9 cycloalkyl, oxo, -C(O)R^a, -C(O)OR^b, -CN, -C(O)NR^cR^d, -NR^cR^d, -$NR^cC(O)R^a$, -$NR^cS(O)_nR^e$, -$NR^cS(O)_nNR^fR^g$, -$NR^cC(O)OR^b$, -$NR^cC(O)NR^dR^e$, -NO_2, -OR^b, -$S(O)_nR^e$, -$S(O)_nNR^cR^d$, halo, halo C_1-C_6 alkyl, heteroaryl, and heterocycle;

R^a, R^b, R^c, R^d, R^e, R^f and R^g are each independently chosen from H, C_1-C_6 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl C_6-C_{14} aryl, optionally substituted with C_1-C_6 alkyl or halo, C_3-C_9 cycloalkyl, halo C_1-C_6 alkyl, heteroaryl, and heterocycle,

or R^a and R^c, and/or R^c and R^d, and/or R^c and R^e, and/or R^c and R^f, and/or R^d and R^e, and /or R^g and R^f together with the atom(s) to which they are attached, form a 3-10 membered heterocycle ring; and


for each occurrence, n is independently 0, 1 , or 2.

2. The compound according to Claim 1, wherein said R^3 is chosen from H, OH, CN, NO_2, halo, C_1-C_6 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, C_6-C_{14} aryl, C_3-C_9 cycloalkyl, heteroaryl, and heterocycle, wherein each of the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycle is optionally substituted by one or more groups independently chosen from C_1-C_6 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, C_6-C_{14}aryl, C_3-C_9 cycloalkyl, -OH, oxo,

$-C(O)R^a$, $-C(O)OR^b$, -CN, $-C(O)NR^cR^d$, $-NR^cR^d$, $-NR^cC(O)R^a$, $-NR^cS(O)_nR^e$, $-NR^cS(O)_nNR^fR^g$, $-NR^cC(O)OR^b$, $-NR^cC(O)NR^dR^e$, $-NO_2$, OR^b, $-S(O)_nR^e$, $-S(O)_nNR^cR^d$, halo, halo C_1-C_6 alkyl, heteroaryl, and heterocycle optionally substituted with –C(O) C_1-C_4 alkyl, further wherein each of alkyl is optionally substituted with –CN or -OH.

3. The compound according to Claim2, wherein said R^3 is chosen from H, C_1-C_6 alkyl, C_6-C_{14} aryl, C_3-C_9 cycloalkyl, heteroaryl, and heterocycle, wherein each of the alkyl, aryl, cycloalkyl, heteroaryl, and heterocycle is optionally substituted by one or more groups independently chosen from C_1-C_6 alkyl -OH, $-C(O)R^a$, -CN, $-NR^cR^d$, $-OR^b$, $-S(O)_nR^e$, $-S(O)_nNR^cR^d$, halo, and heterocycle optionally substituted with –C(O) C_1-C_4 alkyl, further wherein each of alkyl is optionally substituted with –CN or -OH.


4. The compound according to Claim 1, wherein R^1 is a heteroaryl chosen from the following structures



wherein each of which is optionally substituted by one or more groups independently chosen from C_1-C_6 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, aryl, C_3-C_9 cycloalkyl, halo C_1-C_6 alkyl, heteroaryl, heterocycle, oxo, -$C(O)R^a$, -$C(O)OR^b$, -CN, -$C(O)NR^cR^d$, -NR^cR^d, -$NR^cC(O)R^a$, -$NR^cS(O)_nR^e$, -$NR^cS(O)_nNR^fR^g$, -$NR^cC(O)OR^b$, -$NR^cC(O)NR^dR^e$, -NO_2, -OR^b, -$OC(O)R^a$, -$OC(O)NR^cR^d$, -$S(O)_nR^e$, -$S(O)_nNR^cR^d$ and halo;

wherein R^a, R^b, R^c, R^d, R^e, R^f and R^g are each independently chosen from H, C_1-C_6 alkyl, C_6-C_{14} aryl, C_3-C_9 cycloalkyl, halo C_1-C_6 alkyl, heteroaryl, and heterocycle, further wherein each of the alkyl, aryl, cycloalkyl, heteroaryl, and heterocycle in R^a, R^b, R^c, R^d, R^e, R^f and R^g is optionally substituted by one or more substitutents independently selected from halo and C_1-C_6 alkyl.


5 . The compound according to Claim 4, wherein R^1 is a heteroaryl chosen from



wherein each of which is optionally substituted by one or more groups independently chosen from C_1-C_6 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, C_6-C_{14} aryl, C_3-C_9 cycloalkyl, halo C_1-C_6 alkyl, heteroaryl, heterocycle, oxo, $-C(O)R^a$, $-C(O)OR^b$, -CN, $-C(O)NR^cR^d$, $-NR^cR^d$, $-NR^cC(O)R^a$, $-NR^cS(O)_nR^e$, $-NR^cS(O)_nNR^fR^g$, $-NR^cC(O)OR^b$, $-NR^cC(O)NR^dR^e$, $-NO_2$, $-OR^b$, $-OC(O)R^a$, $-OC(O)NR^cR^d$, $-S(O)_nR^e$, $-S(O)_nNR^cR^d$ and halo;

wherein R^a, R^b, R^c, R^d, R^e, R^f and R^g are each independently chosen from H, C_1-C_6 alkyl, C_6-C_{14} aryl, C_3-C_9 cycloalkyl, halo C_1-C_6 alkyl, heteroaryl, and heterocycle, further wherein each of the alkyl, aryl, cycloalkyl, heteroaryl, and heterocycle in R^a, R^b, R^c, R^d, R^e, R^f and R^g is optionally substituted by one or more substitutents independently selected from halo and C_1-C_6 alkyl.

6. The compound according to Claim 4, wherein R^1 is a heteroaryl chosen from



wherein each of which is optionally substituted by one or more groups independently chosen from C_1-C_6 alkyl, haloalkyl, $-NR^cR^d$, $-NR^cS(O)_nR^e$, and halo;

wherein, R^b, R^c, R^d, and R^e are each independently chosen from H, C_1-C_6 alkyl, C_6-C_{14} aryl, C_3-C_9 cycloalkyl, halo C_1-C_6 alkyl, further wherein aryl, in R^b, R^c, R^d, and R^e is optionally substituted by one or more substitutents independently selected from halo and C_1-C_6 alkyl.

7. The compound according to Claim 6 , wherein R^1 is ,
which is optionally substituted with one or more groups independently chosen from:

- halo C_1-C_6 alkyi,;

-NR^cR^d;

-OR^b;


-halo;








-$NR^cS(O)_nR^e$,









wherein R^b, R^c, R^d, and R^e are each independently chosen from H, C_1-C_6 alkyl, aryl, C_3-C_9 cycloalkyl, halo C_1-C_6 alkyl, , wherein aryl in R^b, R^c, R^d and R^e is optionally substituted by one or more substitutents independently selected from halo and C_1-C_6 alkyl.








8. A compound selected from following compounds and/or at least one








pharmaceutically acceptable salt:








Compound	Structure
49	








50	
51	
52	
53	
54	
55	
56	








57	
58	
59	
60	
61	
62	
63	
64	








65	
66	
67	
68	
69	
70	
71	








72	
73	
74	
75	
76	
77	
78	

79	
80	
81	
82	
83	
84	
85	

86	
87	
147	
148	
149	
150	
152	

155	
156	
157	
158	
161	
162	
163	

164	
165	
167	
168	
169	
170	
171	

172	
174	
175	
179	
180	
181	
182	

9. A pharmaceutical composition comprising at least one compound and/or at least one pharmaceutically acceptable salt thereof according to any one of Claims 1 -8 and at least one pharmaceutically acceptable carrier.

10. A method of inhibiting the activity of PI3K and/or mTOR comprising contacting the enzyme with an effective amount of at least one compound and/or at least one pharmaceutically acceptable salt thereof according to any one of Claims 1 -8.

11. A use of at least one compound and/or at least one pharmaceutically acceptable salt thereof according to any one of Claims 1 -8 in the manufacture of a medicament for inhibiting the activity of PI3K and/or mTOR.

12. A use of at least one compound and/or at least one pharmaceutically acceptable salt thereof according to any one of Claims 1 -8 in the manufacture of a medicament for treating cancer.